ENZ-Enzo Biochem Stock Research, Ratings, and Analysis

Enzo Biochem (enz) Stock Research

Last Updated by Anonymous | Update This Page Now

►Summary | Profile | News | Chart | SWOT | Cash Flow | Comps | Buffett | WACC

Long Term Rating Stock Ratings Help

HOLD

SWOT Statistics enz SWOT Analysis

Strengths + Opportunities = 0

Threats + Weaknesses = 0

Add your knowledge to the Enzo Biochem SWOT analysis.

Generic Strategy enz Generic Strategy

Narrow Scope

Broad Scope

None

Uniqueness

Low Cost

Generic strategies categorize companies by the scope and the strength of their business. Enzo Biochem does not have a definable strategy, therefore, it risks losing out to firms that concentrate on one particular competitive advantage. (read more).

Company Description: Enzo Biochem, Inc., founded in 1976, researches and develops genetic engineering, bioTechnology, and molecular biology related products. Its Life Sciences segment develops biomedical research products for research and pharmaceutical customers. The Therapeutics segment researches therapeutic drug candidates for the treatment of gastrointestinal, infectious, and other diseases. The Clinical Labs segment conducts clinical diagnostic laboratory tests, and operates a network of 23 patient service centers as well as a phlebotomy department. Headquartered in New York, New York, Enzo Biochem products are sold internationally. Update

Market Research Update

Health Care Industry Research & Analysis: The health care industry depends on the care of health-related services by professionals for the benefit of patients. Medical device markers, insurance companies, pharmaceutical drug developers and government institutions are major participants in the treatment of sick, injured and disabled patients. Health Care Trading Strategy: Health Care stocks tend to be less sensitive to economic changes. Look for undervalued health care investments at any point in the business cycle when stock prices are low. However, biotech, employment staffing and insurance companies may all decrease during recessions for different reasons. Government intervention is another important factor in health care investments, since government spending in health care is a very large portion of overall health care spending. When governments change spending plans, different sub-sectors in the industry are significantly affected. Upward sloping stock charts and financial news may indicate a selling opportunity while the opposite means that stocks are becoming undervalued.

Industry Sub Sector: . Enzo Biochem is a dominant industry leader due to its personnel, experience and financial strengths. Industry leaders are difficult to compete against, which decreases business and investor risks.

Market Challenges: Opportunities: Solutions:

Strategy Analysis Update

Enzo Biochem's strategy is to continuously improve. This helps to fend against competitive threats and increases shareholder returns.

Strategy: Competitive Advantages:

Financial Analysis Update

Current Revenue Sources: Future Revenue Sources: